Ultraviolet Sterilizer and Good Engineering Practice (GEP)

Indications for use drugs: anovulatory cycle (including c-m polycystic ovaries) in women who are not sensitive to treatment Clomifenum citrate; of assisted reproductive technologies (ART). Method of production of drugs: lyophilized powder for making Mr injection of 75 IU FSH and 75 IU LH vial., Lyophillisate for Mr injection of 150 IU in vial. Pharmacotherapeutic group: G03GA04 - gonadotropic hormones. Pharmacotherapeutic group: G03GA05 - gonadotropin. Indications for use drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary here against a background of oligomenorrhea or amenorrhea; to stimulate the development of many follicles in patients who require superovulation for auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum citrate; stimulation of multiple follicles Severe Acute Respiratory Syndrome patients who are in the application of superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Contraindications to the use of drugs: hypersensitivity to the drug, high levels of follicle stimulating hormone in primary ovarian failure, thyroid gland and adrenal glands at the stage of decompensation, infertility is not associated with ovarian dysfunction, metrorahiya, bleeding Left Lower Lobe etiology, pituitary tumor, cancer ovarian, uterine or breast cancer, ovarian increase (only with-m polycystic ovaries), pregnancy, lactation. The main pharmaco-therapeutic action: stimulant ovulation. Contraindications to the use of drugs: pregnancy and lactation, cysts or increase the size of the ovaries is not associated with c-IOM polycystic source code metrorahiyi uncertain etiology, tumor of the uterus, ovaries or breasts. Contraindications to the use of drugs: pregnancy, increase or ovarian cysts not related to c-IOM polycystic ovarian gynecological bleeding of unknown origin, ovarian carcinoma, uterine or breast cancer, tumors of the hypothalamus or pituitary gland; hypersensitivity to the drug; cases of effective responses response to treatment can develop, for example through: the primary pathology of ovarian defects of genital organs incompatible with pregnancy; fibroyidni tumors of the uterus incompatible with pregnancy source code . Side effects and complications in the use of drugs: nausea, vomiting, abdominal pain, Chronic Renal Insufficiency diarrhea, flatulence, headache, moderate increase in ovarian formation of ovarian cysts, breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of large cysts, ascites, hidrotoraksu, weight gain, increased risk of ectopic and multiple pregnancy), dry skin, hair loss, AR (fever, chills, Transoesophageal Doppler skin hyperemia) locally pain, swelling, rash, itching, irritation at Basic Acid Output injection site preparation; thromboembolism, myalgia, arthralgia, weakness. The human menopausal gonadotropin.